Epiprotect® Demonstrates Significantly Lower Infection Risk in Major Pediatric Study

An independent study published in the Journal of Plastic, Reconstructive & Aesthetic Surgery, conducted at Nottingham Children’s Hospital, shows positive results for Epiprotect®. The study highlights significant pain relief, safety, and quick and easy patient follow-ups. Involving 99 patients aged 0 - 18 years treated for partial-thickness burns, the study reveals that Epiprotect® has comparable acute healing outcomes to Biobrane® from Smith & Nephew, but with a significantly lower infection rate (2.6% compared to 16.4%).

"It is highly significant for S2Medical that high-quality studies like this confirm the benefits we have experienced during our journey to introduce Epiprotect® to the global market. That Epiprotect® now proves to reduce infection risks compared to one of the previously leading products is an enormously important finding, especially since infections in children can mean the difference between life and death," says the company's CEO, Petter Sivlér.

The company expects that the results will accelerate the commercialization of Epiprotect products, leading to increased royalty revenues and enhancing the potential for additional payments for Epiprotect.

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-06-2024 10:32 CET.